{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T07:00:52Z","timestamp":1773990052600,"version":"3.50.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI15\/00820"],"award-info":[{"award-number":["PI15\/00820"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Osteogenesis Imperfecta (OI) is a rare genetic disease characterized by bone fragility, with a wide range in the severity of clinical manifestations. The majority of cases are due to mutations in <jats:italic>COL1A1<\/jats:italic> or <jats:italic>COL1A2<\/jats:italic>, which encode type I collagen. There is no cure for OI, and real concerns exist for current therapeutic approaches, mainly antiresorptive drugs, regarding their effectiveness and security. Safer and effective therapeutic approaches are demanded. Cell therapy with mesenchymal stem cells (MSCs), osteoprogenitors capable of secreting type I collagen, has been tested to treat pediatric OI with encouraging outcomes. Another therapeutic approach currently under clinical development focuses on the inhibition of TGF-\u03b2 pathway, based on the excessive TGF-\u03b2 signaling found in the skeleton of severe OI mice models, and the fact that TGF-\u03b2 neutralizing antibody treatment rescued bone phenotypes in those OI murine models. An increased serum expression of TGF-\u03b2 superfamily members has been described for a number of bone pathologies, but still it has not been addressed in OI patients. To delve into this unexplored question, in the present study we investigated serum TGF-\u03b2 signalling pathway in two OI pediatric patients who participated in TERCELOI, a phase I clinical trial based on reiterative infusions of MSCs. We examined not only the expression and bioactivity of circulating TGF-\u03b2 pathway in TERCELOI patients, but also the effects that MSCs therapy could elicit. Strikingly, basal serum from the most severe patient showed an enhanced expression of several TGF-\u03b2 superfamily members and increased TGF-\u03b2 bioactivity, which were modulated after MSCs therapy.<\/jats:p>","DOI":"10.3389\/fcell.2022.830928","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T07:51:31Z","timestamp":1644393091000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Circulating TGF-\u03b2 Pathway in Osteogenesis Imperfecta Pediatric Patients Subjected to MSCs-Based Cell Therapy"],"prefix":"10.3389","volume":"10","author":[{"given":"Arantza","family":"Infante","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leire","family":"Cabodevilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Gener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara I.","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e36511","DOI":"10.5812\/ijem.36511","article-title":"Transforming Growth Factor \u03b21 (TGF-\u03921) in the Sera of Postmenopausal Osteoporotic Females","volume":"14","author":"Faraji","year":"2016","journal-title":"Int. J. Endocrinol. Metab."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/j.ijcard.2013.03.033","article-title":"Circulating Transforming Growth Factor-\u03b2 as a Prognostic Biomarker in Marfan Syndrome","volume":"168","author":"Franken","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000055910","article-title":"Increased Cell Surface Expression of Receptors for Transforming Growth Factor-\u03b2 on Osteoblasts from Patients with Osteogenesis Imperfecta","volume":"68","author":"Gebken","year":"2000","journal-title":"Pathobiology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.5966\/sctm.2013-0090","article-title":"Pre- and Postnatal Transplantation of Fetal Mesenchymal Stem Cells in Osteogenesis Imperfecta: a Two-center Experience","volume":"3","author":"G\u00f6therstr\u00f6m","year":"2014","journal-title":"Stem Cell Transl Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nm.3544","article-title":"Excessive Transforming Growth Factor-\u03b2 Signaling Is a Common Mechanism in Osteogenesis Imperfecta","volume":"20","author":"Grafe","year":"2014","journal-title":"Nat. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s001980050163","article-title":"The Role of Serum TGF-\u03b2 Isoforms as Potential Markers of Osteoporosis","volume":"9","author":"Grainger","year":"1999","journal-title":"Osteoporos. Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e10530","DOI":"10.1002\/jbm4.10530","article-title":"Inhibition of TGF-\u03b2 Increases Bone Volume and Strength in a Mouse Model of Osteogenesis Imperfecta","volume":"5","author":"Greene","year":"2021","journal-title":"JBMR Plus"},{"key":"B8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1055\/s-2001-15109","article-title":"TGFbeta1 and TGFbeta2 mRNA and Protein Expression in Human Bone Samples","volume":"109","author":"Hering","year":"2001","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"B9","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s00421-001-0537-5","article-title":"Circulating Transforming Growth Factor Beta1 (TGFbeta1) Is Elevated by Extensive Exercise","volume":"86","author":"Hering","year":"2002","journal-title":"Eur. J. Appl. Physiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"8932","DOI":"10.1073\/pnas.132252399","article-title":"Isolated Allogeneic Bone Marrow-Derived Mesenchymal Cells Engraft and Stimulate Growth in Children with Osteogenesis Imperfecta: Implications for Cell Therapy of Bone","volume":"99","author":"Horwitz","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/6529","article-title":"Transplantability and Therapeutic Effects of Bone Marrow-Derived Mesenchymal Cells in Children with Osteogenesis Imperfecta","volume":"5","author":"Horwitz","year":"1999","journal-title":"Nat. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1002\/ctm2.265","article-title":"Reiterative Infusions of MSCs Improve Pediatric Osteogenesis Imperfecta Eliciting a Pro-osteogenic Paracrine Response: TERCELOI Clinical Trial","volume":"11","author":"Infante","year":"2021","journal-title":"Clin. Transl Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1210\/endrev\/bnab017","article-title":"Osteogenesis Imperfecta: Mechanisms and Signaling Pathways Connecting Classical and Rare OI Types","volume":"43","author":"Jovanovic","year":"2021","journal-title":"Endocr. Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"a022269","DOI":"10.1210\/endrev\/bnab017","article-title":"TGF-\u03b2 Family Signaling in Connective Tissue and Skeletal Diseases","volume":"9","author":"MacFarlane","year":"2017","journal-title":"Cold Spring Harb Perspect. Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/s41431-019-0373-x","article-title":"Genotype-phenotype Correlation Study in 364 Osteogenesis Imperfecta Italian Patients","volume":"27","author":"Maioli","year":"2019","journal-title":"Eur. J. Hum. Genet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","article-title":"Osteogenesis Imperfecta","volume":"3","author":"Marini","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/humu.20429","article-title":"Consortium for Osteogenesis Imperfecta Mutations in the Helical Domain of Type I Collagen: Regions Rich in Lethal Mutations Align with Collagen Binding Sites for Integrins and Proteoglycans","volume":"28","author":"Marini","year":"2007","journal-title":"Hum. Mutat."},{"key":"B18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cytogfr.2020.09.003","article-title":"Receptor Binding Competition: A Paradigm for Regulating TGF-\u03b2 Family Action","volume":"57","author":"Martinez-Hackert","year":"2021","journal-title":"Cytokine Growth Factor. Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1161\/circulationaha.108.841981","article-title":"Circulating Transforming Growth Factor-\u03b2 in Marfan Syndrome","volume":"120","author":"Matt","year":"2009","journal-title":"Circulation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/abbs\/gmx126","article-title":"TGF-\u03b2 Family Co-receptor Function and Signaling","volume":"50","author":"Nickel","year":"2018","journal-title":"Acta Biochim. Biophys. Sin (Shanghai)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jcyt.2017.09.012","article-title":"Extracellular Vesicles Released from Mesenchymal Stromal Cells Stimulate Bone Growth in Osteogenesis Imperfecta","volume":"20","author":"Otsuru","year":"2018","journal-title":"Cytotherapy"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4857","DOI":"10.1073\/pnas.92.11.4857","article-title":"Cultured Adherent Cells from Marrow Can Serve as Long-Lasting Precursor Cells for Bone, Cartilage, and Lung in Irradiated Mice","volume":"92","author":"Pereira","year":"1995","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.injury.2011.03.055","article-title":"Elevated Transforming Growth Factor-Beta 1 (TGF-\u03921) Levels in Human Fracture Healing","volume":"42","author":"Sarahrudi","year":"2011","journal-title":"Injury"},{"key":"B24","doi-asserted-by":"publisher","first-page":"12559","DOI":"10.1074\/jbc.ra120.012492","article-title":"Targeting All Transforming Growth Factor-\u03b2 Isoforms with an Fc Chimeric Receptor Impairs Tumor Growth and Angiogenesis of Oral Squamous Cell Cancer","volume":"295","author":"Takahashi","year":"2020","journal-title":"J. Biol. Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/jbmr.3617","article-title":"Effect of Anti\u2010TGF\u2010\u03b2 Treatment in a Mouse Model of Severe Osteogenesis Imperfecta","volume":"34","author":"Tauer","year":"2018","journal-title":"J. Bone Miner Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e10174","DOI":"10.1002\/jbm4.10174","article-title":"Osteogenesis Imperfecta: New Perspectives from Clinical and Translational Research","volume":"3","author":"Tauer","year":"2019","journal-title":"JBMR Plus"},{"key":"B27","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41467-018-02988-5","article-title":"Inhibition of Overactive TGF-\u03b2 Attenuates Progression of Heterotopic Ossification in Mice","volume":"9","author":"Wang","year":"2018","journal-title":"Nat. Commun."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1210\/jc.2017-01150","article-title":"Multiple Soluble TGF-\u03b2 Receptors in Addition to Soluble Endoglin Are Elevated in Preeclamptic Serum and They Synergistically Inhibit TGF-\u03b2 Signaling","volume":"102","author":"Wang","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B29","doi-asserted-by":"publisher","first-page":"eaax2271","DOI":"10.1126\/sciadv.aax2271","article-title":"An Array of 60,000 Antibodies for Proteome-Scale Antibody Generation and Target Discovery","volume":"6","author":"Wang","year":"2020","journal-title":"Sci. Adv."},{"key":"B30","doi-asserted-by":"publisher","first-page":"727164","DOI":"10.1155\/2013\/727164","article-title":"Relationship between Serum Levels of OPG and TGF- \u03b2 with Decreasing Rate of BMD in Native Chinese Women","volume":"2013","author":"Wu","year":"2013","journal-title":"Int. J. Endocrinol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/nm.3143","article-title":"Inhibition of TGF-\u03b2 Signaling in Mesenchymal Stem Cells of Subchondral Bone Attenuates Osteoarthritis","volume":"19","author":"Zhen","year":"2013","journal-title":"Nat. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.bone.2005.02.011","article-title":"TGF-\u03b21 as a Marker of Delayed Fracture Healingg","volume":"36","author":"Zimmermann","year":"2005","journal-title":"Bone"}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2022.830928\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T07:51:37Z","timestamp":1644393097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2022.830928\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":32,"alternative-id":["10.3389\/fcell.2022.830928"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2022.830928","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,9]]},"article-number":"830928"}}